Chai Discovery, a pioneering biotech company leveraging artificial intelligence to predict and reprogram interactions among biochemical molecules, has recently raised an impressive $70 million in a Series A funding round. This funding was spearheaded by Menlo Ventures, alongside investments from Anthology Fund—a collaboration with Anthropic. Noteworthy participants in this funding round include Yosemite, DST Global Partners, SV Angel, Avenir, and DCVC, as well as existing investors like Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam.
One of Chai Discovery’s latest milestones is the unveiling of Chai-2, a cutting-edge series of models that have been shown to achieve remarkable double-digit hit rates in de novo antibody design. De novo drug design, as defined by the International Journal of Molecular Sciences, represents a computational strategy that generates entirely novel molecular structures from fundamental building blocks without prior relationships. This innovative approach diverges from traditional methods like structure-based and ligand-based design, which hinge on either the properties of a biological target’s active site or its known active binders, respectively.
Chai-2’s standout capability lies in its capacity to develop successful binders against a diverse array of targets with minimal input—merely the target antigen and epitope. By empowering scientists to design entirely new antibodies from scratch tailored to specific antigens like disease-causing proteins or viruses, Chai Discovery’s technology represents a significant leap in accelerating drug discovery and development processes. The company has emphasized that this advancement is crucial in overcoming the sluggish pace of innovation in the field, often hindered by costly and time-consuming trial-and-error experiments.
Joshua Meier, the CEO and co-founder of Chai Discovery, expressed the company’s commitment to transforming the landscape of biotechnology by applying cutting-edge AI to revolutionize biology into a more engineering-centric discipline. This shift aims to enable the deliberate design of breakthrough therapies and drugs, rather than relying solely on chance discoveries. The newly secured funds will be instrumental in further enhancing the Chai platform and facilitating partnerships with select collaborators to drive innovation and accelerate drug development.
Chai Discovery’s success and vision resonate with the broader landscape of companies operating in the de novo antibody design sphere, such as Absci. Notably, Absci recently collaborated with AMD to leverage advanced AI models for de novo antibody design, powered by AMD Instinct accelerators and ROCm software. This strategic partnership, supported by a substantial $20 million investment from AMD, underscores the industry’s commitment to leveraging AI tools and complex biological modeling to expedite the creation of biologics for patient care.
Key Takeaways:
– Chai Discovery secured $70 million in Series A funding, led by Menlo Ventures, to advance its AI-driven de novo antibody design capabilities.
– Chai-2, the latest model from Chai Discovery, enables the rapid and efficient design of novel antibodies against a wide range of targets with minimal inputs.
– The company’s mission to transform biology into an engineering discipline through frontier AI applications aims to accelerate drug discovery and development.
– Collaborations between companies like Absci and AMD underscore the industry’s focus on leveraging AI and advanced technologies for innovative biologic design.
Read more on mobihealthnews.com